ANI Pharmaceuticals, Inc.
ANIP
$44.67
-$0.54-1.19%
Rating Factors
Growth Index
Efficiency Index
--
Solvency Index
Total Return Index
Volatility Index
Dividend Index
--
Headlines
1/24/2023
-
Tickeron - Technical Analysis
1/22/2023
-
Zolmax
1/21/2023
-
Tickeron - Technical Analysis
1/11/2023
-
Zolmax
1/11/2023
-
Ticker Report
1/10/2023
-
Tickeron - Stocks
1/9/2023
-
ETF Channel
1/8/2023
-
Simply Wall St
1/7/2023
-
Tickeron - Technical Analysis
1/7/2023
-
Tickeron - Stocks
1/7/2023
-
Tickeron - Stocks
1/5/2023
-
Tickeron - Stocks
1/1/2023
-
Seeking Alpha - Long Ideas
12/30/2022
-
Tickeron - Stocks
12/29/2022
-
Ticker Report
12/20/2022
-
Zolmax
12/19/2022
-
SeekingAlpha.com: All News
12/19/2022
-
Business Wire
12/3/2022
-
Zolmax
12/3/2022
-
Tickeron - Stocks
11/28/2022
-
Business Wire
11/27/2022
-
Ticker Report
11/23/2022
-
Zolmax
11/19/2022
-
Tickeron - Stocks
11/17/2022
-
Ticker Report
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Wednesday, November 9, 2022
Period Date
Friday, September 30, 2022
Next Filing
Week of Mar 13 and 17 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
218 634 3500
Address
210 Main Street West
Baudette, MN 56623
Baudette, MN 56623
Country
Year Founded
Business Description
Sector
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on...
more